The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
The company’s Growth Portfolio delivered $6.2 billion in revenue
Lifts full-year outlook as obesity drug boom accelerates
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
The Danish biotech company confirmed the global study will begin in the second half of 2026
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
